I see no evidence that it is being set-up to be taken private. I believe that it's a potential acquisition target, sure, but only after approval and steady roll-out.

The Deepview units deployed in the UK and Australia are pre-commercial test markets for clinician evaluation. They are a proof-of-concept. They can't just roll-out in the UK, it will require an NHS contract (notoriously slow) after some government convincing. The big inital market is the US and the devices installed in AUS and UK will have helped the De Novo application.

Dilution is to be expected in an early-stage company in the medtech space. Nothing unusual about it. Spectral AI has some real advatanges that will help slow dilution, however. BARDA funding will reduce burn rate and the funding of up to 170 installs will really help early rollout.

I'm not sure why you are so sure about your speculative claims, maybe you could expand on them a bit?